Lanthanide cancer therapies
Development of theranostics for precision targeting of EBV-associated tumours.
This joint laboratory will focus on the developing of dual-modality theranostic techniques (Optical and magnetic resonance imaging - MRI) for inhibition of EBV-associated cancers.
This research project, a collaboration between HKBU and CAS, focused on developing theranostic agents to target Epstein-Barr virus (EBV)-associated cancers by combining therapy and diagnostic imaging. The aims were to create biocompatible lanthanide-based agents that released anticancer drugs when activated by near-infrared light, while also serving as dual-imaging contrast agents for optical imaging (OI) and magnetic resonance imaging (MRI). By investigating the pharmacokinetics and bio-distribution of these agents in vivo using mouse models, the project sought to enhance their therapeutic effectiveness. It also involved the development of advanced microscopy systems for evaluating these agents. Targeting the EBNA1 protein, crucial for EBV-related tumourigenesis, created the potential to inhibit EBV-associated cancers effectively.
-
Original project funded for three years from 2018
Directors
Ka-Leung Wong
Professor at Hong Kong Baptist University
Jun Lin
Professor Situation unknown
Other projects
Adult stem cell regeneration
Original project funded for three years from 2024
Chiral electronic materials
Original project funded for three years from 2024
Extreme temperature electronics
Original project funded for three years from 2022
Glioma drug resistance
Original project funded for three years from 2024
Stay in the loop!
Subscribe to keep up with the latest from Croucher Foundation.